| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc. | General Counsel, Secretary | Common Stock | 28,125 | $60,469 | $2.15 | 22 Feb 2024 | Direct |
| Ovid Therapeutics Inc. | General Counsel, Secretary | Stock Option (Right to Buy) | 168,750 | 22 Feb 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | 22 Feb 2024 | 2 | $0 | 4 | General Counsel, Secretary | 26 Feb 2024, 18:00 |
| OVID | Ovid Therapeutics Inc. | 23 Feb 2023 | 1 | $0 | 4 | General Counsel, Secretary | 27 Feb 2023, 16:00 |
| OVID | Ovid Therapeutics Inc. | 08 Apr 2022 | 2 | $0 | 4 | General Counsel, Secretary | 12 Apr 2022, 17:30 |
| OVID | Ovid Therapeutics Inc. | 03 Feb 2022 | 1 | $0 | 4 | General Counsel, Secretary | 04 Feb 2022, 17:19 |